Komori
Kaken Pharmaceutical (4521) · PolicyRestated

Enhancing corporate governance and accountability

First written in FY2017. 5 of 6 entries say "Restated". Latest entry: FY2026.

6entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20262017: 120172018: 120182019: 120192020: 020202021: 120212022: 120222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Transparent and Honest Management and Stakeholder DialogueA theme 93 companies write about · 0 as a headwind · 94 as a tailwind

64 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 93 companies compared. The sentences above are computed from all 93.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「We regard enhancing corporate governance and ensuring management transparency and accountability to stakeholders as among our most important management priorities.」

    The basic stance of treating corporate governance, management transparency and accountability to stakeholders as important priorities continues.
  2. FY2022RestatedAnnual report

    「We regard enhancing corporate governance and ensuring management transparency and accountability to stakeholders as among our most important management priorities.」

    The policy of treating corporate governance, management transparency and accountability to stakeholders as important priorities continues.
  3. FY2021RestatedAnnual report

    「We regard enhancing corporate governance and ensuring management transparency and accountability to stakeholders as among our most important management priorities.」

    The policy of treating enhanced corporate governance, management transparency and accountability to stakeholders as important priorities continues.
  4. FY2019RestatedAnnual report

    「We regard enhancing corporate governance and ensuring management transparency and accountability to stakeholders as among our most important management priorities.」

    The basic stance of treating corporate governance, management transparency and accountability to stakeholders as important priorities continues.
  5. FY2018RestatedAnnual report

    「We regard enhancing corporate governance and ensuring management transparency and accountability to stakeholders as among our most important management priorities.」

    The policy of treating corporate governance, management transparency and accountability to stakeholders as important priorities continues.
  6. FY2017First statedAnnual report

    「We regard enhancing corporate governance and ensuring management transparency and accountability to stakeholders as among our most important management priorities.」

    Enhancing corporate governance, management transparency and accountability to stakeholders are positioned as important priorities.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.